CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 669 enrolled / 669 target
Drug / intervention
Durvalumab (MEDI4736) +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03003962
NCT03003962Phase 3ActiveUpdate Overdue (5.9/mo)Completion was 44mo ago
CompareCT.gov

A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer

AstraZeneca·interventional·Posted Dec 28, 2016·Updated Jun 11, 2026

In Brief

A Phase 3 clinical trial evaluating Durvalumab (MEDI4736), Paclitaxel + carboplatin, and 4 other interventions for Non Small Cell Lung Carcinoma NSCLC. Active but no longer recruiting, targeting 669 participants across 92 sites in 12 countries.

Signals

Enrollment appears stalled

Detailed Summary

This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Carcinoma NSCLC
CountriesAustralia, China, Hungary, Netherlands, Poland, Russia, South Korea, Taiwan, Thailand, Turkey (Türkiye), United States, Vietnam
Collaborators--

Timeline

Phase 3ActiveOverdue
2017201820192020202120222023202420252026
First PostedDec 28, 2016
Enrollment StartJan 2, 2017
Primary CompletionOct 27, 2022
Study CompletionJun 30, 2026
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 9.5 years ago

Arms & Interventions

Arm 1: Durvalumabexperimental

Anti-PD-L1 monoclonal Antibody monotherapy

Drug: Durvalumab (MEDI4736)
Arm 2: Standard of Careactive_comparator

Standard of Care Platinum-Based chemotherapy

Drug: Paclitaxel + carboplatinDrug: Gemcitabine + cisplatinDrug: Gemcitabine + carboplatinDrug: Pemetrexed + cisplatinDrug: Pemetrexed + carboplatin

Interventions

Durvalumab (MEDI4736)drug

Anti-PD-L1 monoclonal Antibody monotherapy

Paclitaxel + carboplatindrug

Chemotherapy Agents

Gemcitabine + cisplatindrug

Chemotherapy Agents

Gemcitabine + carboplatindrug

Chemotherapy Agents

Pemetrexed + cisplatindrug

Chemotherapy Agent

Pemetrexed + carboplatindrug

Chemotherapy Agent